focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

Tue, 11th Aug 2015 14:15

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews.By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta Resources losing most of the ground that it had gained on Monday.Other mid-cap basic resources hit as the dollar appreciated 1.8% against China's yuan included copper producer Kaz Minerals, Premier Oil and platinum miner Lonmin.Although its shares gained initially, Just Retirement was firmly in the red later in the day after agreeing a 60-40 merger in its favour with annuities rival Partnership Assurance to create a new £1.7bn company.Woodford Patient Capital Trust, one of the funds run by star fund manager Neil Woodford, was lower despite after publishing first half-year results since listing in April this year, with the shares trading at an 11% premium to net assets value per share. But the shares were hit by the announcement of a tap issuance programme to satisfy excess demand in the secondary market, but the new shares issued will be done so at a premium to NAV and should therefore be accretive to existing shareholders.Building materials group SIG fell despite posting a rise in first-half pre-tax profit and raising its interim dividend. The company said its margins were under pressure, with variable trading conditions in Europe and a significant weakening of the euro which hit revenues.Leading the 250 risers on Tuesday was Synthomer, as the latex maker reported a first-half profit before tax of £51.4m, up 14% from the first half of last year. The company said the performance was strong given significant exchange rate headwinds, and warned its full year result could suffer if conditions continued.Online and catalogue retailer N Brown was lifted despite the release of mixed UK retail sales data from the BRC. Online non-food sales rose by 14.7%, higher than expected, but ladieswear had a disappointing month, though accessories, kidswear and summer footwear enjoyed strong sales.Allied Minds, after being revealed as one of the stocks in the Woodford Patient Capital Trust's top ten holdings, was another big gainer. (4d Pharma and Vernalis, an AIM company, also gained strongly later in the session, though Imperial Innovations was a faller, disproving any Woodford-based stock picking strategies.)FTSE 250 - RisersSynthomer (SYNT) 350.80p +6.40%Allied Minds (ALM) 471.50p +5.88%Zoopla Property Group (WI) (ZPLA) 257.90p +5.65%Nostrum Oil & Gas (NOG) 570.00p +3.92%Euromoney Institutional Investor (ERM) 1,115.00p +3.82%Cineworld Group (CINE) 550.00p +3.38%Centamin (DI) (CEY) 55.05p +2.42%Evraz (EVR) 97.75p +2.20%Brown (N.) Group (BWNG) 322.00p +2.09%Acacia Mining (ACA) 241.20p +1.99%FTSE 250 - FallersVedanta Resources (VED) 468.00p -4.76%Shawbrook Group (SHAW) 324.60p -4.36%Kaz Minerals (KAZ) 156.70p -3.81% Just Retirement Group (JRG) 191.20p -3.77%Woodford Patient Capital Trust (WPCT) 115.50p -3.19%Premier Oil (PMO) 119.50p -3.00%Lonmin (LMI) 43.05p -2.93%SIG (SHI) 196.10p -2.58%Brewin Dolphin Holdings (BRW) 301.00p -2.40%Ocado Group (OCDO) 374.30p -2.32%
More News
14 May 2018 16:11

UK Shareholder Meetings Calendar - Next 7 Days

Tuesday 15 MayAmerisur ResourcesMacfarlane GroupSpirax-Sarco EngineeringAnglo Pacific

Read more
8 May 2018 10:02

4D Pharma Sets Up Phase Two Study For Bowel Syndrome Treatment Blautix

LONDON (Alliance News) - Biotherapeutics developer 4D Pharma PLC said on Tuesday that the US Food & Drug Administration has cleared the Investigational New Drug Application for irritable bowel

Read more
23 Apr 2018 09:47

4D Pharma Loss In 2017 Widens On Higher Research And Development Costs

LONDON (Alliance News) - Drug development firm 4D Pharma PLC said Monday its loss widened in 2017 on higher research and development costs as it continued to progress its pipeline and clinical in

Read more
21 Mar 2018 09:12

4D Pharma To Shortly Begin Clinical Studies On MRx0518 Treatment

LONDON (Alliance News) - 4D Pharma PLC on Wednesday said it is close to starting clinical studies on its potential MRx0518 cancer treatment.MRx0518 is a single strain a

Read more
13 Dec 2016 07:54

4D Pharma Reports Encouraging Results From Blautix Phase 1 Trial

Read more
30 Sep 2016 06:51

4D Pharma Loss Narrows As Operating And Research Costs Fall

Read more
22 Aug 2016 11:57

4D Pharma begins Thetanix phase 1 clinical trial

(ShareCast News) - Pharmaceutical company 4D pharma has begun dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease (PCD). PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading to inflammation, or sw

Read more
19 Jul 2016 10:00

4D Pharma announces encouraging first clinical trial of Blautix

(ShareCast News) - 4D Pharma announced a positive response from its Blautix treatment for irritable bowel syndrome (IBS) in a phase 1 clinical trial. The trial was a first in man study and, as previously reported by the company, Blautix was found to be both safe and well tolerated and achieved the p

Read more
19 Jul 2016 07:49

4D Pharma Says Positive First Trial Of Product Blautix "Encouraging"

Read more
10 Jun 2016 07:30

4D Pharma Gets Approval To Restart Thetanix Phase I Clinical Study

Read more
23 May 2016 12:49

4D Pharma irritable bowel treatment proves safe in clinical trial

(ShareCast News) - Early clinical trials of 4D Pharma's treatment for irritable bowel syndrome (IBS) have successfully shown Blautix to be safe and well tolerated. Blautix, which contains live bacteria, like all 4D's products, was delivered orally to 56 healthy volunteers and IBS patients. Data fro

Read more
23 May 2016 06:58

4d Pharma Says Blautix Treatment Meets Primary Endpoint In Trial

Read more
17 May 2016 15:11

AGM, EGM Calendar - Week Ahead

Read more
16 May 2016 15:10

AGM, EGM Calendar - Week Ahead

Read more
8 Apr 2016 16:17

4D Pharma gobbles up Biomar production assets

(ShareCast News) - 4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourc

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.